Interview with Jean Paul Scheuer, General Manager, Sanofi Ukraine
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Address: 48-50A, st. Zhylyanska
Business Center Prime,
01033, Kyiv, Ukraine
Tel: +380 044 354 20 00
Web: http://www.sanofi.ua/l/ua/index.jsp
Sanofi S.A. is a multinational pharmaceutical company headquartered in Paris, France, the world’s fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo. It changed its name to Sanofi in May 2011.
The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world’s largest producer of the latter through its subsidiary Sanofi Pasteur).
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Dr. Natalya Gudz, head of the State Service of Ukraine on Medicines and Drugs Control (SMDC), provides her vision for the development of Ukraine’s key regulatory authority and the win-win…
Denis Shevchenko, founder of the NGO and charitable foundation PharmVarta, provides insights into the main initiatives of this independent, non-profit organization that has freely supplied Ukrainian patients with more than…
Alexander Markus, chairman of the board of the recently set up German-Ukrainian Chamber of Industry and Commerce, provides insights into the new dynamics driving the growth of Ukraine’s foreign trade…
Dr. Volodymyr Redko, executive director of Ukraine’s Association of Pharmaceutical Research and Development (APRaD), which gathers together 15 international R&D-driven companies, provides insights into the perspective of international innovators vis-à-vis…
As the first Ukrainian pharmaceutical company backed by foreign capital, explain to us how the idea of creating “Sperco Ukraine” as a joint-venture with UCRAFARMA emerged? The idea to create…
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Nobel Pharma has quite a history in the CIS region as this region is becoming increasingly important for the company. What is the company’s story in Ukraine? Nobel Pharma Ukraine…
Let us start with the history of InterChem which is quite unique and started as a chemical company with a very small group from the National Academy of Sciences. Please…
It has been almost a decade since Mili Healthcare began its operations in Ukraine today becoming one of the top 20 leading foreign companies in the local industry. What were…
What was the vision behind the creation of APRaD back in 2007 and what was lacking in the market at that time that called for such an association? APRaD originated…
You recently switched from Novartis to Unipharm. Given the major differences in environment and portfolio, what was it about Unipharm in particular that attracted you and what are you bringing…
Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and ratiopharm in 2010, which…
See our Cookie Privacy Policy Here